For more information see www.markherzen.com.

MarkHerz Inc. – Innovating Advanced Biologics with Digital Twin Technology

MarkHerz Inc., established in 2021, is a pioneering company specializing in personalized Cell & Gene Therapy (CGT). The company’s flagship platforms, MAAV and MAAV-UP, leverage AI robotics and digital twin technology to streamline and automate viral vector production for advanced biopharmaceuticals. MarkHerz has established global collaborations in South Korea, Japan, Germany, and Kenya to support clinical trials and aims to achieve global commercialization of its CGT solutions by 2028.

A key milestone includes preclinical success in cardiovascular therapy using large-animal models (pigs), demonstrating a 30% to 70% improvement in heart function and a fivefold reduction in vascular plaque formation. Strategic partnerships with Munich Heart Center, Seoul St. Mary’s Hospital, and Takeda’s Shonan iPark highlight the company’s strong global network. Additionally, MarkHerz is set to establish a clinical research hub in Kenya with USD 50M in ODA funding. To date, the company has secured approximately USD 30M in government R&D funding and plans to raise an additional USD 300M by 2028.

The CGT market is projected to grow at a CAGR of 49.4%, reaching USD 55.59B by 2026, with gene therapies experiencing an even faster CAGR of 59%. MarkHerz’s competitive advantages include patient-specific delivery vectors, automated production systems, and a robust global network.

Currently raising USD 3M in a pre-Series A funding round, MarkHerz will allocate resources to accelerate clinical trials, develop automated systems, and advance R&D efforts. By 2028, the company aims to commercialize its MAAV-UP platform globally, targeting USD 300M in annual revenue.

MarkHerz offers investors a unique opportunity to enter the rapidly growing CGT market, backed by strategic partnerships, innovative technology, and impactful contributions to global healthcare. With its groundbreaking approach, MarkHerz is poised to revolutionize the future of personalized gene therapy.